Reading SMMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SMMT free→Reading SMMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SMMT free→QuarterlyIQ Insights · SMMT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
as if fully set forth herein. On January 12, 2026, the Company issued a press release announcing the submission of a Biologics License Application to U.S. Food and Drug Administration seeking approval for ivonescimab in combination with chemotherapy in second line or later treatment of patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer. A copy of the press release is attached as Exhibit 99.2 to this Current Report on F…
Results of Operations and Financial Conditions. As of December 31, 2025, the preliminary unaudited balance of cash, cash equivalents, and short-term investments of Summit Therapeutics Inc. (the “Company”) was approximately $710 million. This amount is preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s consolidated financial statements for the year ended December 31, 20…
Unregistered Sales of Equity Securities. The information contained in
Entry into a Material Definitive Agreement. On October 21, 2025, Summit Therapeutics Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with multiple leading biotech institutional and individual accredited investors (the “Investors”), for the sale by the Company in a private placement (the “Private Placement”) of an aggregate of 26,682,846 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at purchase…
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. On August 11, 2025, Summit Therapeutics Inc. (the “Company”) entered into an amendment (the “Amendment”) to the distribution agreement with J.P. Morgan Securities LLC (“Sales Agent”), as sales agent, which amended that certain distribution agreement, dated May 13, 2024, by and between the Company and the Sales Agent (the “Original Distribution Agreement” and, as amended by the Amendment, the “Distribution Agreement”). Pursuant to the Amendment, the…
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. Effective June 16, 2025, Summit Therapeutics Inc. (the “Company”) entered into a sub-sublease between Ascendis Pharma, Inc., dated June 2, 2025, for 36,406 square feet of office space in Palo Alto, California (the “Sub-Sublease Agreement”). The effectiveness of the Sub-Sublease Agreement was conditioned upon obtaining the consent of the landlord and the sublandlord to the Sub-Sublease Agreement. The term of the Sub-Sublease Agreement commences on Ja…
and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.